Get started
HANSA BIOPHARMA ABHANSA BIOPHARMA ABHANSA BIOPHARMA AB

HANSA BIOPHARMA AB

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

HNSA chart


Full chart

HNSA upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.53 B‬ SEK
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−13.06 SEK
Net income (FY)
‪−807.24 M‬ SEK
Revenue (FY)
‪171.32 M‬ SEK
Shares float
‪57.73 M‬
Beta (1Y)
0.24

Employees


Employees (FY)
135
Change (1Y)
−33 −19.64%
Revenue / Employee (1Y)
‪1.27 M‬ SEK
Net income / Employee (1Y)
‪−5.98 M‬ SEK

About HANSA BIOPHARMA AB


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Søren Tulstrup
Website
hansabiopharma.com
Headquarters
Lund
Founded
2007
ISIN
SE0002148817
FIGI
BBG000QCYH36
Hansa Biopharma AB focuses on novel immunomodulatory enzymes, which treat rare immunoglobulin G-mediated autoimmune conditions, transplant rejection and cancer. Its pipeline includes IdeS, HBP-assay, EnzE, and NiceR. The company was founded by Lars Björck and Bo Krister Håkansson in 2001 and is headquartered in Lund, Sweden.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

HNSA news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as HNSA.

Frequently Asked Questions


The current price of HNSA is 23.76 SEK — it has decreased by −0.89% in the past 24 hours. Watch HANSA BIOPHARMA AB stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange HANSA BIOPHARMA AB stocks are traded under the ticker HNSA.
HNSA stock has risen by 5.79% compared to the previous week, the month change is a −6.14% fall, over the last year HANSA BIOPHARMA AB has showed a −15.02% decrease.
We've gathered analysts' opinions on HANSA BIOPHARMA AB future price: according to them, HNSA price has a max estimate of 143.00 SEK and a min estimate of 32.00 SEK. Watch HNSA chart and read a more detailed HANSA BIOPHARMA AB stock forecast: see what analysts think of HANSA BIOPHARMA AB and suggest that you do with its stocks.
HNSA reached its all-time high on Oct 4, 2018 with the price of 349.40 SEK, and its all-time low was 2.26 SEK and was reached on Oct 23, 2012. View more price dynamics on HNSA chart.
See other stocks reaching their highest and lowest prices.
HNSA stock is 23.10% volatile and has beta coefficient of 0.24. Track HANSA BIOPHARMA AB stock price on the chart and check out the list of the most volatile stocks — is HANSA BIOPHARMA AB there?
Today HANSA BIOPHARMA AB has the market capitalization of ‪1.51 B‬, it has increased by 0.46% over the last week.
Yes, you can track HANSA BIOPHARMA AB financials in yearly and quarterly reports right on TradingView.
HANSA BIOPHARMA AB is going to release the next earnings report on Jul 17, 2025. Keep track of upcoming events with our Earnings Calendar.
HNSA earnings for the last quarter are −0.55 SEK per share, whereas the estimation was −2.67 SEK resulting in a 79.43% surprise. The estimated earnings for the next quarter are −2.50 SEK per share. See more details about HANSA BIOPHARMA AB earnings.
HANSA BIOPHARMA AB revenue for the last quarter amounts to ‪66.30 M‬ SEK, despite the estimated figure of ‪49.24 M‬ SEK. In the next quarter, revenue is expected to reach ‪66.36 M‬ SEK.
HNSA net income for the last quarter is ‪−276.42 M‬ SEK, while the quarter before that showed ‪−103.80 M‬ SEK of net income which accounts for −166.31% change. Track more HANSA BIOPHARMA AB financial stats to get the full picture.
No, HNSA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 24, 2025, the company has 135 employees. See our rating of the largest employees — is HANSA BIOPHARMA AB on this list?
Like other stocks, HNSA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HANSA BIOPHARMA AB stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So HANSA BIOPHARMA AB technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating HANSA BIOPHARMA AB stock shows the sell signal. See more of HANSA BIOPHARMA AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.